BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of ($0.16), $0.05 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $430 million versus the consensus estimate of $418.61 million.

GUIDANCE:

BioMarin Pharma sees 2020 revenue of $1.85-1.95 billion, versus the consensus of $1.9 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.